SNGX - Soligenix Inc Stock Price, Fair Value and News

0.39USD-0.01 (-2.50%)Delayed as of 24 Apr 2024, 12:11 pm ET

Market Summary

USD0.39-0.01

Delayedas of 24 Apr 2024, 12:11 pm

-2.50%

SNGX Stock Price

View Fullscreen

SNGX RSI Chart

SNGX Valuation

Market Cap

4.2M

Price/Earnings (Trailing)

-0.69

Price/Sales (Trailing)

5.02

EV/EBITDA

0.18

Price/Free Cashflow

-0.49

SNGX Price/Sales (Trailing)

SNGX Profitability

Operating Margin

11.59%

EBT Margin

-942.21%

Return on Equity

-243.45%

Return on Assets

-62.68%

Free Cashflow Yield

-204.38%

SNGX Fundamentals

SNGX Revenue

Revenue (TTM)

839.4K

Rev. Growth (Yr)

-33.12%

Rev. Growth (Qtr)

87.68%

SNGX Earnings

Earnings (TTM)

-6.1M

Earnings Growth (Yr)

51.52%

Earnings Growth (Qtr)

-9.45%

Breaking Down SNGX Revenue

52 Week Range

0.394.20

(Low)(High)

Last 7 days

-14.9%

Last 30 days

-36.5%

Last 90 days

-32.2%

Trailing 12 Months

-74.0%

How does SNGX drawdown profile look like?

SNGX Financial Health

Current Ratio

1.55

Debt/Equity

1.15

Debt/Cashflow

-2.97

SNGX Investor Care

Shares Dilution (1Y)

256.81%

Diluted EPS (TTM)

-0.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.0M	996.3K	960.6K	839.4K
2022	864.7K	878.6K	858.5K	948.9K
2021	1.6M	1.3M	869.4K	824.3K
2020	4.4M	3.4M	2.7M	2.4M
2019	5.3M	5.1M	5.0M	4.6M
2018	5.2M	6.0M	5.5M	5.2M
2017	0	8.1M	7.3M	5.4M
2016	0	0	0	0
2015	0	0	0	0
2014	3.2M	4.0M	6.5M	1.5M
2013	3.2M	3.2M	2.8M	3.2M
2012	6.1M	6.4M	2.3M	0
2011	3.0M	4.1M	5.1M	6.2M
2010	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Soligenix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 18, 2022	schaber christopher j	bought	8,866	0.4433	20,000	chairman, ceo and president
May 18, 2022	straube richard	bought	4,000	0.5	8,000	senior vice president and cmo
Dec 17, 2021	schaber christopher j	bought	5,179	0.7399	7,000	chairman, ceo and president
Dec 15, 2021	guarino jonathan l.	bought	700	0.7	1,000	senior vice president and cfo
Dec 14, 2021	schaber christopher j	bought	7,269	0.7269	10,000	chairman, ceo and president
Dec 14, 2021	guarino jonathan l.	bought	7,119	0.7119	10,000	senior vice president and cfo
May 14, 2021	zeldis jerome b	sold	-2,700	0.9002	-3,000	-
May 14, 2021	zeldis jerome b	bought	2,664	0.888	3,000	-
Nov 19, 2019	schaber christopher j	bought	10,016	0.93	10,770	chairman, ceo and president
Nov 19, 2019	zeldis jerome b	bought	1,850	0.925	2,000	-

Which funds bought or sold SNGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	unchanged	-	-1.00	3.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	90.04	23,594	38,515	-%
Feb 29, 2024	Scarborough Advisors, LLC	new	-	47.00	47.00	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	4.00	15.00	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	sold off	-100	-412,864,000	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-7,460	-	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	8,885	8,885	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	13,435	13,435	-%
Feb 13, 2024	BlackRock Inc.	added	6,316	60,368	61,069	-%

Are Funds Buying or Selling SNGX?

Are funds buying SNGX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNGX

No. of Funds

Unveiling Soligenix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 06, 2020	altamont pharmaceutical holdings, llc	2.6%	678,338	SC 13G/A
Apr 23, 2020	altamont phamaceutical holdings, llc	5.0%	1,278,338	SC 13G/A
Feb 07, 2020	act capital management, lllp	5.6%	1,221,499	SC 13G/A

Recent SEC filings of Soligenix Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	PRE 14A	PRE 14A
Apr 19, 2024	424B4	Prospectus Filed
Apr 15, 2024	EFFECT	EFFECT
Apr 03, 2024	8-K	Current Report
Apr 02, 2024	S-1/A	Initial Public Offering
Mar 15, 2024	S-1/A	Initial Public Offering
Mar 15, 2024	10-K	Annual Report
Jan 16, 2024	S-1	Initial Public Offering

Peers (Alternatives to Soligenix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Soligenix Inc News

Latest updates

Soligenix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	87.7%	244,812	130,440	206,929	257,178	366,068	166,140	228,640	188,063	275,653	186,198	214,824	147,593	320,795	608,811	505,288	924,552	685,261	1,254,904	1,544,964	1,144,788	1,014,778
Cost Of Revenue	100.6%	221,546	110,441	184,021	226,040	135,865	129,440	193,304	92,213	235,698	166,265	204,317	122,360	241,464	386,641	363,339	829,506	587,224	965,453	1,086,814	927,924	887,888
Gross Profit	16.3%	23,266	19,999	22,908	31,138	230,203	36,700	35,336	95,850	39,955	19,933	10,507	25,233	79,332	222,170	141,949	95,046	98,037	289,451	458,150	216,864	126,890
Operating Expenses	20.1%	2,161,137	1,799,055	1,653,232	2,181,827	3,800,181	3,117,944	3,430,632	4,288,236	4,551,738	3,384,844	2,999,166	2,258,840	5,565,399	2,034,947	2,955,821	8,568,838	3,407,505	3,056,050	2,623,041	2,516,927	3,283,891
S&GA Expenses	42.2%	1,383,603	973,040	890,533	1,235,376	1,442,394	1,326,249	1,382,793	2,541,468	1,849,583	1,147,279	1,062,558	949,318	1,905,975	768,420	785,776	868,667	1,048,362	789,251	769,091	874,209	905,981
R&D Expenses	-5.9%	777,534	826,015	762,699	946,451	2,357,787	1,791,695	2,047,839	1,746,768	2,702,155	2,237,565	1,936,608	1,309,522	3,659,424	1,266,527	2,170,045	2,700,171	2,359,143	2,266,799	1,853,950	1,642,718	2,377,910
EBITDA Margin	1.3%	-8.76	-8.88	-10.04	-11.72	-14.82	-16.84	-17.26	-17.12	-16.08	-17.13	-9.96	-8.00	-7.83	-5.74	-	-	-	-	-	-	-
Interest Expenses	1.1%	64,047	63,351	211,170	213,490	213,490	211,170	208,850	223,901	768,836	-216,800	-214,750	-213,505	-35,332	486	2,017	21,947	-	-	-	-	-
Income Taxes	-Infinity%	-606,606	-	-	-1,161,197	-	-1,154,935	-1,154,935	-	431,305	-864,742	-864,742	2,132	-	-	-	-836,893	-	-	-	-610,676	-
Earnings Before Taxes	-45.9%	-2,426,501	-1,662,702	-1,612,024	-2,207,306	-3,753,555	-3,309,003	-3,541,695	-4,349,021	-4,703,876	-3,587,551	-2,761,810	-2,362,478	-5,540,265	-1,790,160	-2,776,763	-8,418,227	-2,871,661	-2,720,783	-2,123,521	-2,250,303	-3,104,819
EBT Margin	2.0%	-9.42	-9.61	-10.92	-12.58	-15.76	-18.52	-18.42	-17.81	-16.28	-16.39	-9.64	-7.88	-7.85	-5.82	-	-	-	-	-	-	-
Net Income	-9.5%	-1,819,895	-1,662,702	-1,612,024	-1,046,109	-3,753,555	-3,309,003	-2,386,760	-4,349,021	-4,703,876	-3,587,551	-1,897,068	-2,362,478	-5,540,265	-1,790,160	-2,776,763	-7,581,334	-2,871,661	-2,720,783	-2,123,521	-1,639,627	-3,104,819
Net Income Margin	13.0%	-7.32	-8.41	-9.76	-10.31	-14.54	-17.18	-17.10	-16.81	-15.23	-15.40	-8.97	-7.88	-7.50	-5.51	-	-	-	-	-	-	-
Free Cashflow	31.9%	-1,828,213	-2,686,316	-1,923,327	-2,166,253	-3,627,141	-3,254,977	-2,528,060	-3,238,843	-3,055,354	-3,040,119	-1,658,920	-3,985,227	-4,124,955	-2,990,941	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-13.3%	9,797	11,303	13,826	11,102	14,280	17,947	21,312	23,675	26,870	29,718	29,610	31,552	19,891	13,250	12,261	9,848	7,775	8,332	9,193	9,521	10,492
Current Assets	-13.3%	9,507	10,972	13,471	10,722	13,853	17,493	20,826	23,474	26,570	29,445	29,353	31,280	19,467	12,730	11,977	9,569	7,493	8,010	8,812	9,128	10,343
Cash Equivalents	-18.0%	8,446	10,299	13,161	10,266	13,360	16,866	20,158	22,876	26,044	28,867	28,980	30,542	18,677	11,343	11,168	7,203	5,421	6,552	6,986	7,200	8,984
Net PPE	-11.8%	12.00	14.00	15.00	17.00	18.00	22.00	26.00	28.00	22.00	14.00	17.00	20.00	24.00	28.00	33.00	38.00	36.00	10.00	12.00	16.00	20.00
Liabilities	2.7%	7,275	7,082	8,026	14,489	16,751	16,915	17,107	17,090	16,147	14,663	14,014	14,234	16,149	5,845	6,230	6,333	6,318	5,654	5,557	4,240	4,212
Current Liabilities	11.4%	6,152	5,522	5,758	11,377	16,517	9,666	8,840	7,224	6,291	4,796	4,125	4,301	6,081	5,536	5,996	6,329	6,312	5,634	5,500	4,148	4,212
Long Term Debt	-28.6%	1,011	1,416	2,094	2,908	-	6,887	7,877	9,866	9,856	9,846	9,835	9,824	9,860	-	-	-	-	-	-	-	-
LT Debt, Current	50.0%	2,250	1,500	750	6,000	9,898	3,000	2,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-40.2%	2,522	4,221	5,800	-	-2,470	1,032	4,206	6,584	10,723	15,055	15,596	17,319	3,742	7,405	6,031	3,515	1,457	2,678	3,636	5,282	6,280
Retained Earnings	-0.8%	-225,704	-223,884	-222,221	-220,609	-219,563	-215,809	-212,500	-210,114	-205,765	-201,061	-197,473	-195,576	-193,214	-187,673	-185,883	-183,106	-175,525	-172,653	-169,933	-167,809	-166,170
Additional Paid-In Capital	0.1%	228,194	228,071	228,006	217,207	217,065	216,773	216,653	216,531	216,443	216,024	213,062	212,891	196,950	195,059	191,923	186,625	177,006	175,326	173,558	173,076	172,436
Accumulated Depreciation	1.3%	121	120	118	117	115	112	107	172	168	164	161	-	155	-	-	-	-	-	-	-	-
Shares Outstanding	0%	10,378	10,378	9,842	2,930	2,909	2,867	2,864	2,861	2,858	2,713	2,672	2,455	2,043	-	-	-	-	-	-	-	-
Float	-	-	-	6,847	-	-	-	25,735	-	-	-	39,976	-	-	-	57,300	-	-	-	9,584	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	31.9%	-1,828	-2,686	-1,923	-2,166	-3,627	-3,254	-2,528	-3,238	-3,055	-3,040	-1,658	-3,985	-4,124	-2,990	-1,643	-2,695	-2,643	-2,057	-515	-2,293	-2,675
Share Based Compensation	115.8%	141	65.00	90.00	74.00	113	71.00	72.00	78.00	106	80.00	81.00	95.00	199	67.00	81.00	64.00	142	82.00	73.00	80.00	118
Cashflow From Investing	-	-	-	-	-	-	-	-3.25	-9.82	-	-	-	-	-	-	-	-7.15	-30.21	-	-	-	999*
Cashflow From Financing	73.7%	-46.18	-175	4,817	-931	-	-	-	-	251	2,863	89.00	15,856	11,435	3,109	5,618	4,516	1,559	1,637	304	505	-59.76

SNGX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Total revenues	$ 839,359	$ 948,911
Cost of revenues	(742,048)	(550,822)
Gross profit	97,311	398,089
Operating expenses:
Research and development	3,312,699	7,944,089
General and administrative	4,482,552	6,692,904
Total operating expenses	7,795,251	14,636,993
Loss from operations	(7,697,940)	(14,238,904)
Other income (expense):
Foreign currency transaction gain (loss)	1,483	(30,549)
Interest income (expense), net	(49,129)	(822,611)
Research and development incentives	23,784	132,869
CARES Act Employee Retention Credit	120,771
Other income	43,223	5,921
Loss on extinguishment of debt	(393,791)
Change in fair value of convertible debt	43,066
Total other income (expense)	(210,593)	(714,370)
Net loss before income taxes	(7,908,533)	(14,953,274)
Income tax benefit	1,767,803	1,154,935
Net loss applicable to common stockholders	$ (6,140,730)	$ (13,798,339)
Basic net loss per share (in Dollars per share)	$ (0.79)	$ (4.81)
Diluted net loss per share (in Dollars per share)	$ (0.79)	$ (4.81)
Basic weighted average common shares outstanding (in Shares)	7,758,036	2,871,345
Diluted weighted average common shares outstanding (in Shares)	7,758,036	2,871,345
Licensing revenue
Total revenues		$ 250,000
Grant revenue
Total revenues	$ 839,359	$ 698,911

SNGX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,446,158	$ 13,359,615
Contracts and grants receivable		115,130
Unbilled revenue	171,254
Research and development incentives receivable, current	23,894	104,198
Prepaid expenses and other current assets	866,014	274,209
Total current assets	9,507,320	13,853,152
Security deposit	22,777	22,777
Office furniture and equipment, net of accumulated depreciation of $121,320 and $114,766	11,927	18,481
Deferred issuance cost		20,206
Right-of-use lease assets	229,834	340,987
Research and development incentives receivable, net of current portion	25,468	24,114
Total assets	9,797,326	14,279,717
Current liabilities:
Accounts payable	1,111,226	3,865,796
Accrued expenses	2,418,002	2,307,746
Accrued compensation	251,115	336,692
Lease liabilities, current	121,765	108,948
Convertible debt, net of debt discount of $0 and $102,309	2,250,000	9,897,691
Total current liabilities	6,152,108	16,516,873
Non-current liabilities:
Convertible debt	1,010,934	0
Lease liabilities, net of current portion	111,862	233,627
Total liabilities	7,274,904	16,750,500
Commitments and contingencies (Note 10)
Series D preferred stock, $.001 par value; 0 and 50,000 shares authorized, none issued or outstanding as of December 31, 2023 and December 31, 2022, respectively		43
Shareholders' equity/(deficit):
Preferred stock, 350,000 and 300,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; none issued or outstanding
Common stock, $.001 par value; 75,000,000 shares authorized; 10,378,238 and 2,908,578 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	10,378	2,909
Additional paid-in capital	228,193,977	217,064,964
Accumulated other comprehensive income	22,243	24,747
Accumulated deficit	(225,704,176)	(219,563,446)
Total shareholders' equity/(deficit)	2,522,422	(2,470,826)
Total liabilities, mezzanine equity and shareholders' equity/(deficit)	$ 9,797,326	$ 14,279,717

About Soligenix Inc

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

CEO	Dr. Christopher J. Schaber Ph.D.
WEBSITE	soligenix.com
INDUSTRY	Biotechnology
EMPLOYEES	13

Soligenix Inc Frequently Asked Questions

What is the ticker symbol for Soligenix Inc? What does SNGX stand for in stocks?

SNGX is the stock ticker symbol of Soligenix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Soligenix Inc (SNGX)?

As of Tue Apr 23 2024, market cap of Soligenix Inc is 4.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNGX stock?

You can check SNGX's fair value in chart for subscribers.

What is the fair value of SNGX stock?

You can check SNGX's fair value in chart for subscribers. The fair value of Soligenix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Soligenix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Soligenix Inc a good stock to buy?

The fair value guage provides a quick view whether SNGX is over valued or under valued. Whether Soligenix Inc is cheap or expensive depends on the assumptions which impact Soligenix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNGX.

What is Soligenix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, SNGX's PE ratio (Price to Earnings) is -0.69 and Price to Sales (PS) ratio is 5.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNGX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Soligenix Inc's stock?

In the past 10 years, Soligenix Inc has provided -0.339 (multiply by 100 for percentage) rate of return.